glp-1 articles Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response GLP-1 Medications and Their Place

Strecker The study was done before any recommendations were adopted specific to GLP-1s and when to stop the medication prior to surgery, Strecker said in her presentation at the American Academy of Orthopaedic Surgeons Annual Meeting

The absolute incidence of pancreatitis in clinical trials has been consistently low across studies, typically affecting fewer than 1 in 200 patients over multi-year follow-up periods

and BMI at baseline (3035, 3540, and 40 kg/m 2 )

Pichette J, Fynn-Sackey N, Gagnon J

doi: 10.1093/asj/sjad240 [DOI] [PubMed] [Google Scholar] 28

It functions as a dual GLP-1 and GIP receptor agonist , offering: Enhanced insulin secretion Delayed gastric emptying Appetite suppression Improved glycemic control Tirzepatide demonstrated impressive clinical outcomes in the SURMOUNT and SURPASS trials, with average weight loss of 15-22.5% and substantial A1C reductions